New reagents for improved in vitro and in vivo examination of TGF-β signalling

Growth Factors

Volumn 29, Issue 5, 2011, Pages 211-218

  Luwor, Rodney B ^a   Wang, Bo ^a   Nheu, Thao V ^a   Iaria, Josephine ^a   Tsantikos, Evelyn ^b,c   Hibbs, Margaret L ^b,c   Sieber, Oliver M ^b   Zhu, Hong Jian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Adenovirus; Luciferase; TGF signalling

Indexed keywords

SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN 3T3; CYTOMEGALOVIRUS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; GENES, REPORTER; HEK293 CELLS; HUMANS; MICE; NIH 3T3 CELLS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRIDAE; MUS;

EID: 80052872201     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2011.615311     Document Type: Article

References (46)

1. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. 1999. Elevated levels of circulating interleukin-6 and transforming growth factor-βeta1 in patients with metastatic prostatic carcinoma. J Urol 161:182-187. (Pubitemid 29422316)
2. Arai T, Akiyama Y, Okabe S, Ando M, Endo M, Yuasa Y. 1998. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. Cancer Lett 122:157-163. (Pubitemid 28058631)
3. Ashktorab H, Schaffer AA, Daremipouran M, Smoot DT, Lee E, Brim H. 2010. Distinct genetic alterations in colorectal cancer. PLoS One 5:e8879.
4. Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358. (Pubitemid 30408720)
5. Brown PD, Wakefield LM, Levinson AD, Sporn MB. 1990. Physicochemical activation of recombinant latent transforming growth factor-βeta's 1, 2, and 3. Growth Factors 3:35-43. (Pubitemid 20265013)
6. Chau MN, Banerjee PP. 2008. Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors. Biochem Biophys Res Commun 377: 627-631.
7. Chen YS, Mathias RA, Mathivanan S, Kapp EA, Moritz RL, Zhu HJ, Simpson RJ. 2011. M110 001131 Proteomics profiling of Madin-Darby canine kidney plasma membranes reveals Wnt-5a involvement during oncogenic H-Ras/ BRI-βeta-mediated epithelial-mesenchymal transition. Mol Cell Proteomics 10: M110 001131.
8. Culhaci N, Sagol O, Karademir S, Astarcioglu H, Astarcioglu I, Soyturk M, Oztop I, Obuz F. 2005. Expression of transforming growth factor-βeta-1 and p27Kip1 in pancreatic adenocarcinomas: Relation with cell-cycle-associated proteins and clinicopathologic characteristics. BMC Cancer 5:98-105.
9. Das P, Maduzia LL, Padgett RW. 1999. Genetic approaches to BRI-β signaling pathways. Cytokine Growth Factor Rev 10: 179-186. (Pubitemid 30041398)
10. de Larco JE, Todaro GJ. 1978. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 75: 4001-4005. (Pubitemid 8399860)
11. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. 1998. Direct binding of Smad3 and Smad4 to critical BRI-β betainducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091-3100. (Pubitemid 28254381)
12. Derynck R, Akhurst RJ, Balmain A. 2001. BRI-βeta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129. (Pubitemid 32952643)
13. Ding Z,Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, De Pinho RA. 2011. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470:269-273.
14. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC. 2003. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610-2615. (Pubitemid 36605203)
15. Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, Schiraldi O, Antonaci S. 2002. Transforming growth factorbeta1 triggers hepatocellular carcinoma invasiveness via alpha3 beta1 integrin. Am J Pathol 161:183-193. (Pubitemid 34760784)
16. Gordon KJ, Blobe GC. 2008. Role of transforming growth factorbeta superfamily signaling pathways in human disease. Biochim Biophys Acta 1782:197-228.
17. Grady WM, Willis JE, Trobridge P, Romero-Gallo J, Munoz N, Olechnowicz J, Ferguson K, Gautam S, Markowitz SD. 2006. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with BRI-βBR2 mutations. Int J Cancer 118: 600-608. (Pubitemid 43076008)
18. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE. 1996. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56:490-494. (Pubitemid 26043644)
19. Han SU, Kim HT, Seong DH, Kim YS, Park YS, Bang YJ, Yang HK, Kim SJ. 2004. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 23:1333-1341. (Pubitemid 38406829)
20. Heldin CH, Miyazono K, ten Dijke P. 1997. BRI-βeta signaling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471. (Pubitemid 28013118)
21. Heldin CH, Landstrom M, Moustakas A. 2009. Mechanism of BRI-βeta signaling to growth arrest, apoptosis, and epithelialmesenchymal transition. Curr Opin Cell Biol 21:166-176.
22. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, Yabuuchi I, Matsuda Y, Nishioka M, Tarui S. 1991. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 51:4080-4083.
23. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjogren HO, Widegren B. 2000. Expression of BRI-βeta isoforms, BRI-βeta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89:251-258. (Pubitemid 30430741)
24. Konrad L, Scheiber JA, Schwarz L, Schrader AJ, Hofmann R. 2009. BRI-βeta1 and BRI-βeta2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3. Regul Pept 155: 28-32.
25. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. 2009. Imaging transforming growth factor-βeta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 15:960-966.
26. Levy L, Howell M, Das D, Harkin S, Episkopou V, Hill CS. 2007. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. Mol Cell Biol 27: 6068-6083. (Pubitemid 47326695)
27. Luo J, Lin AH, Masliah E, Wyss-Coray T. 2006. Bioluminescence imaging of Smad signaling in living mice shows correlation with excitotoxic neurodegeneration. Proc Natl Acad Sci USA 103: 18326-18331. (Pubitemid 44871657)
28. Luwor RB, Kaye AH, Zhu HJ. 2008. Transforming growth factorbeta ( BRI-βeta) and brain tumours. J Clin Neurosci 15: 845-855.
29. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV. 1995. Inactivation of the type II BRI-βeta receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338.
30. Massague J. 2008. BRI-β in Cancer. Cell 134:215-230.
31. Massague J, Gomis RR. 2006. The logic of BRI-β signaling. FEBS Lett 580:2811-2820.
32. Meulmeester E, Ten Dijke P. 2011. The dynamic roles of BRI-βeta in cancer. J Pathol 223:205-218.
33. Miyazono K, Olofsson A, Colosetti P, Heldin CH. 1991. A role of the latent BRI-βeta 1-βinding protein in the assembly and secretion of BRI-βeta 1. EMBO J 10:1091-1101. (Pubitemid 21905570)
34. Moustakas A, Heldin CH. 2005. Non-Smad BRI-βeta signals. J Cell Sci 118:3573-3584.
35. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. 1995. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55:5548-5550.
36. Serganova I, Moroz E, Vider J, Gogiberidze G, Moroz M, Pillarsetty N, Doubrovin M, Minn A, Thaler HT, Massague J, Gelovani J, Blasberg R. 2009. Multimodality imaging of BRI-β signaling in breast cancer metastases. Faseb J 23:2662-2672.
37. Siegel PM, Massague J. 2003. Cytostatic and apoptotic actions of BRI-βeta in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
38. Stravodimos K, Constantinides C, Manousakas T, Pavlaki C, Pantazopoulos D, Giannopoulos A, Dimopoulos C. 2000. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: Divergent correlation with clinicopathological parameters. Anticancer Res 20:3823-3828. (Pubitemid 32002282)
39. Taipale J, Miyazono K, Heldin CH, Keski-Oja J. 1994. Latent transforming growth factor-βeta 1 associates to fibroblast extracellular matrix via latent BRI-βeta binding protein. J Cell Biol 124:171-181. (Pubitemid 24054619)
40. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton SR, Kern SE, KinzlerKW, Vogelstein B. 1996. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13:343-346. (Pubitemid 26230501)
41. Tian M, Neil JR, Schiemann WP. 2011. Transforming growth factor-βeta and the hallmarks of cancer. Cell Signal 23:951-962.
42. Tsantikos E, Quilici C, Harder KW, Wang B, Zhu HJ, Anderson GP, Tarlinton DM, Hibbs ML. 2009. Perturbation of the CD4 T cell compartment and expansion of regulatory T cells in autoimmune-prone Lyn-deficient mice. J Immunol 183: 2484-2494.
43. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. 1998. SARA, a FYVE domain protein that recruits Smad2 to the BRI-β receptor. Cell 95:779-791. (Pubitemid 29014458)
44. Xu L, Chen YG, Massague J. 2000. The nuclear import function of Smad2 is masked by SARA and unmasked by BRI-βdependent phosphorylation. Nat Cell Biol 2:559-562.
45. Zhang J, Lu Y, Dai J, Yao Z, Kitazawa R, Kitazawa S, Zhao X, Hall DE, Pienta KJ, Keller ET. 2004. In vivo real-time imaging of BRI-βeta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. Prostate 59:360-369. (Pubitemid 38661803)
46. Zhu HJ, Burgess AW. 2001. Regulation of transforming growth factor-βeta signaling. Mol Cell Biol Res Commun 4:321-330. (Pubitemid 33098102)